-0.12%
7.92%
-31.63%
-18.62%
-70.14%
-14.19%
-57.01%
AI Spotlight on EYPT
Company Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC.It also has a commercial alliance with ImprimisRx PA, Inc.for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery.
The company was formerly known as pSivida Corp.and changed its name to EyePoint Pharmaceuticals, Inc.in March 2018.
EyePoint Pharmaceuticals, Inc.was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Market Data
| Last Price | 8.04 |
| Change Percentage | -0.12% |
| Open | 8.04 |
| Previous Close | 8.05 |
| Market Cap ( Millions) | 549 |
| Volume | 14985 |
| Year High | 30.99 |
| Year Low | 6.9 |
| M A 50 | 8.21 |
| M A 200 | 9.98 |
Financial Ratios
| FCF Yield | -20.27% |
| Dividend Yield | 0.00% |
| ROE | -43.01% |
| Debt / Equity | 10.02% |
| Net Debt / EBIDTA | 56.60% |
| Price To Book | 2.12 |
| Price Earnings Ratio | -4.48 |
| Price To FCF | -4.93 |
| Price To sales | 12.74 |
| EV / EBITDA | -5.12 |
News
- Jan -30 - EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
- Jan -30 - EyePoint to Present at Guggenheim SMID Cap Biotech Conference
- Jan -16 - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Jan -08 - EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.
- Dec -16 - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Dec -04 - EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
- Nov -14 - EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
- Nov -13 - Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
- Nov -07 - EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
- Nov -04 - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Oct -31 - EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
- Oct -30 - EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
- Oct -29 - EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
- Oct -28 - EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Oct -28 - EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
- Oct -24 - EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
- Oct -16 - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Sep -04 - EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
- Aug -29 - EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
- Aug -27 - EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> License and Collaboration Agreements
Expected Growth : 9.27 %
What the company do ?
EyePoint Pharmaceuticals, Inc.'s License and Collaboration Agreements involve partnerships for developing and commercializing ophthalmic products, outlining terms for research, development, and revenue sharing.
Why we expect these perspectives ?
EyePoint Pharmaceuticals' 9.27% growth in License and Collaboration Agreements is driven by increasing demand for ophthalmic treatments, strategic partnerships, and expansion into new markets. The company's innovative pipeline and strong intellectual property portfolio also contribute to its growth, as well as its ability to secure lucrative licensing deals with major pharmaceutical companies.
Segment n°2 -> Ophthalmic Products
Expected Growth : 8.9 %
What the company do ?
EyePoint Pharmaceuticals, Inc.'s ophthalmic products are innovative, sustained-release treatments for serious eye diseases, including macular edema and uveitis.
Why we expect these perspectives ?
EyePoint Pharmaceuticals' 8.9% growth in Ophthalmic Products is driven by increasing demand for innovative treatments, expanding indications for existing products, and strategic partnerships. Growing prevalence of eye diseases, such as diabetic retinopathy and age-related macular degeneration, also contribute to the segment's growth.
Segment n°3 -> Royalty
Expected Growth : 8.9 %
What the company do ?
EyePoint Pharmaceuticals, Inc. receives royalty payments from sales of products utilizing its proprietary Durasert and Verisome technology platforms.
Why we expect these perspectives ?
Strong demand for EyePoint's ophthalmic products, particularly YUTIQ and DEXYCU, drives royalty growth. Increasing adoption in the U.S. and expansion into international markets contribute to the 8.9% growth. Additionally, the company's strategic partnerships and collaborations, such as with Ocumension Therapeutics, further boost revenue.
Eyepoint Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| DEXYCU | DEXYCU is a corticosteroid indicated for the treatment of postoperative inflammation and pain associated with ocular surgery. |
| YUTIQ | YUTIQ is a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. |
| ILUVIEN | ILUVIEN is a fluocinolone acetonide intravitreal implant indicated for the treatment of diabetic macular edema (DME) in patients who have an artificial lens implanted. |
EyePoint Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
EyePoint Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for eye diseases.
Bargaining Power Of Customers
EyePoint Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the presence of insurance companies.
Bargaining Power Of Suppliers
EyePoint Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment.
Threat Of New Entrants
EyePoint Pharmaceuticals, Inc. has a high threat of new entrants due to the growing demand for eye care treatments and the presence of venture capital funding for startups.
Intensity Of Rivalry
EyePoint Pharmaceuticals, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.01% |
| Debt Cost | 12.54% |
| Equity Weight | 97.99% |
| Equity Cost | 12.54% |
| WACC | 12.54% |
| Leverage | 2.05% |
EyePoint Pharmaceuticals, Inc. : Quality Control
EyePoint Pharmaceuticals, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| LPCN | Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| ABUS | Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of … |
| BCRX | BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Arbutus Biopharma
A-Score
1-Year Total Return ->
🥉
Lipocine
A-Score
1-Year Total Return ->
4
BioCryst Pharmaceuticals
A-Score
1-Year Total Return ->
5
Poseida Therapeutics
A-Score
1-Year Total Return ->
6
